Sumitomo Pharma Co., Ltd.

TSE:4506.T

608 (JPY) • At close September 19, 2024
Overview | Financials

Numbers are in millions (except for per share data and ratios) JPY.

20232022202120202019201820172016201520142013201220112010200920082007200620052004
Revenue 314,558555,544560,035515,952482,732459,267466,838411,645403,205371,370387,709347,732350,384379,529296,295264,060263,992261,213245,784175,088
Cost of Revenue 126,577178,919157,127137,773129,673113,553112,345100,078104,470101,227104,117101,69498,845110,047112,297103,76599,38699,346130,437111,099
Gross Profit 187,981376,625402,908378,179353,059345,714354,493311,567298,735270,143283,592246,038251,539269,482183,998160,295164,606161,867115,34763,989
Gross Profit Ratio 0.5980.6780.7190.7330.7310.7530.7590.7570.7410.7270.7310.7080.7180.710.6210.6070.6240.620.4690.365
Reseach & Development Expenses 112,637131,85894,903132,682115,112102,36486,92880,81982,03371,30469,80459,84456,89068,15951,37152,8180000
General & Administrative Expenses 429,538373,316249,081190,373154,348180,439183,651000005,1284,9604,8445,153124,794116,31286,46152,404
Selling & Marketing Expenses 42,37259,85737,78037,36237,74537,97538,21224,08126,96328,8200000000000
SG&A 429,538373,316249,081190,373154,348180,439183,65124,08126,96328,820171,646161,1505,1284,9604,8445,153124,794116,31286,46152,404
Other Expenses 00-1,310-16,1003605,027-4,259-802-749-1,575-1,604-1,291-756-1,354-1,406-651-1000
Operating Expenses 542,175453,604342,674306,955269,820287,830266,320258,805261,802246,864241,448220,992126,123138,87676,87874,650124,793116,31286,46152,404
Operating Income -354,194-76,97960,23471,22483,23957,88488,17352,75936,92923,27542,14225,04320,40230,95135,62431,16639,81345,55528,88611,585
Operating Income Ratio -1.126-0.1390.1080.1380.1720.1260.1890.1280.0920.0630.1090.0720.0580.0820.120.1180.1510.1740.1180.066
Total Other Income Expenses Net 31,08078,42922,99423,5521,0253,774-3,307-5,5462,62810,476-7,435-6,888-109,089-105,557-75,697-53,4771,644-7,140-3,199101
Income Before Tax -323,114-47,92082,96177,85183,94765,04684,86647,21739,56033,75534,70918,15816,32725,04931,42332,16841,45738,41525,68711,686
Income Before Tax Ratio -1.027-0.0860.1480.1510.1740.1420.1820.1150.0980.0910.090.0520.0470.0660.1060.1220.1570.1470.1050.067
Income Tax Expense -8,18548,79442,36141,02248,02916,41931,41818,22614,86318,30714,6488,1147,6988,25310,45812,16915,79015,75210,2394,673
Net Income -314,969-74,51256,41356,21940,75348,62753,44828,99124,69715,44720,06010,0438,62916,79620,95819,98725,59122,60515,3776,924
Net Income Ratio -1.001-0.1340.1010.1090.0840.1060.1140.070.0610.0420.0520.0290.0250.0440.0710.0760.0970.0870.0630.04
EPS -792.79-187.55141.99141.5102.58122.39134.5378.8262.1638.8850.4925.2821.7242.2752.7550.364.3956.8754.5741.76
EPS Diluted -792.79-187.55141.99141.5102.58122.39134.5378.8262.1638.8850.4925.2821.7242.2752.7550.364.3956.8754.5741.76
EBITDA -316,429-3,498124,359103,110104,17279,229103,49073,58855,10741,50468,41460,660165,238174,816124,99697,42251,68358,55040,15820,094
EBITDA Ratio -1.006-0.0060.2220.20.2160.1730.2220.1790.1370.1120.1760.1740.4720.4610.4220.3690.1960.2240.1630.115